Johan Reutfors1, Louise Wingård2, Lena Brandt2, Yiting Wang3, Hong Qiu3, Helle Kieler2, Shahram Bahmanyar2. 1. Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Electronic address: johan.reutfors@ki.se. 2. Centre for Pharmacoepidemiology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 3. Janssen Research and Development, Department of Epidemiology, Titusville, NJ, USA.
Abstract
BACKGROUND: Several antipsychotics, especially risperidone, are known to increase serum prolactin. Hyperprolactinemia has been linked to the development of mammary gland tumors in animal studies. We therefore investigated the risk of breast cancer in a nationwide cohort of women using risperidone or other antipsychotics. METHODS: All women, 18years or older, who initiated treatment with risperidone or any other antipsychotic between 2006 and 2012 were identified in Swedish nationwide registers. Patients with two consecutive dispensations of the same antipsychotic within 3months, no previous cancer diagnosis, and no previous dispensations of paliperidone were included. The final cohort consisted of 55976 women of whom 22908, 24524, and 8544 were exposed to risperidone, other atypical antipsychotics, and typical antipsychotics, respectively. A Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association between antipsychotics and breast cancer. RESULTS: Patients were followed prospectively, the mean follow-up time ranging from 2.4 to 2.8years between treatment groups. After adjusting for age, there was no increased risk for breast cancer among risperidone users compared to patients exposed to another atypical antipsychotic (HR 0.94, 95% CI 0.72-1.22) or a typical antipsychotic (HR 1.25, 95% CI 0.94-1.66). Analyses stratified by tumor stage, using active treatment follow-up time, or including only treatment naïve patients did not reveal any noteworthy change in the results. CONCLUSION: Risperidone use does not confer an increased short-term risk of breast cancer compared to other antipsychotic agents.
BACKGROUND: Several antipsychotics, especially risperidone, are known to increase serum prolactin. Hyperprolactinemia has been linked to the development of mammary gland tumors in animal studies. We therefore investigated the risk of breast cancer in a nationwide cohort of women using risperidone or other antipsychotics. METHODS: All women, 18years or older, who initiated treatment with risperidone or any other antipsychotic between 2006 and 2012 were identified in Swedish nationwide registers. Patients with two consecutive dispensations of the same antipsychotic within 3months, no previous cancer diagnosis, and no previous dispensations of paliperidone were included. The final cohort consisted of 55976 women of whom 22908, 24524, and 8544 were exposed to risperidone, other atypical antipsychotics, and typical antipsychotics, respectively. A Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association between antipsychotics and breast cancer. RESULTS:Patients were followed prospectively, the mean follow-up time ranging from 2.4 to 2.8years between treatment groups. After adjusting for age, there was no increased risk for breast cancer among risperidone users compared to patients exposed to another atypical antipsychotic (HR 0.94, 95% CI 0.72-1.22) or a typical antipsychotic (HR 1.25, 95% CI 0.94-1.66). Analyses stratified by tumor stage, using active treatment follow-up time, or including only treatment naïve patients did not reveal any noteworthy change in the results. CONCLUSION:Risperidone use does not confer an increased short-term risk of breast cancer compared to other antipsychotic agents.
Authors: Anna George; Susan R Sturgeon; Susan E Hankinson; Aladdin H Shadyab; Robert B Wallace; Katherine W Reeves Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-11-04 Impact factor: 4.254
Authors: Tahir Rahman; John M Sahrmann; Margaret A Olsen; Katelin B Nickel; J Phillip Miller; Cynthia Ma; Richard A Grucza Journal: J Clin Psychopharmacol Date: 2022 Jan-Feb 01 Impact factor: 3.153
Authors: Enda M Byrne; Manuel A R Ferreira; Angli Xue; Sara Lindström; Xia Jiang; Jian Yang; Douglas F Easton; Naomi R Wray; Georgia Chenevix-Trench Journal: Schizophr Bull Date: 2019-10-24 Impact factor: 9.306
Authors: Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho Journal: Ther Clin Risk Manag Date: 2017-06-29 Impact factor: 2.423
Authors: A N Johnston; W Bu; S Hein; S Garcia; L Camacho; L Xue; L Qin; C Nagi; S G Hilsenbeck; J Kapali; K Podsypanina; J Nangia; Y Li Journal: Breast Cancer Res Date: 2018-05-19 Impact factor: 6.466
Authors: Blánaid M Hicks; John Busby; Ken Mills; Francis A O'Neil; Stuart A McIntosh; Shu-Dong Zhang; Fabio Giuseppe Liberante; Chris R Cardwell Journal: BMC Cancer Date: 2020-08-24 Impact factor: 4.430